#United States #New York #Kahn Swick #class action lawsuit #Capricor Therapeutics

Class Action Alert for Capricor Therapeutics, Inc.

On September 11, 2026, Kahn Swick & Foti, LLC, a highly regarded law firm known for its securities litigation, announced a critical update for investors regarding Capricor Therapeutics, Inc. This update pertains to a class action lawsuit against the company, with a looming deadline for investor applications set for September 28, 2026. This serves as a significant warning to individuals who invested in Capricor securities during a specified period.

What Is the Lawsuit About?

The lawsuit intends to recover financial losses for those who purchased or acquired Capricor securities between December 17, 2025, and July 26, 2026. This legal action is currently pending in the United States District Court for the Southern District of California. According to the legal team at KSF, Capricor and certain executives are accused of failing to disclose important information that could affect investor decision-making, thereby violating federal securities laws.

The allegations center on claims that Capricor misrepresented essential details relevant to its lead product candidate, Deramiocel, particularly in regard to the adjustments made to its statistical analysis plan prior to the submission of a vital regulatory application.

FDA Findings and Stock Impact

On July 27, 2026, the U.S. Food and Drug Administration (FDA) released briefing documents highlighting concerns over the changes that Capricor made to their statistical analysis plan. The documents indicated that these modifications could undermine the effectiveness of the data being reviewed and that they hadn’t been adequately discussed with the FDA prior to submission. This red flag raised concerns about the reliability of the analyses led by Capricor regarding the efficacy and safety profile of Deramiocel.

The fallout from this announcement was severe; Capricor's stock plunged by 64%, closing at $7.00 per share on July 27, driven by unusually high trading volume. This shares drop underscores the urgency of the situation for affected investors.

Call to Action for Investors

For those who invested in Capricor during the specified timeframe and suffered financial losses, there is still an opportunity to take action. Interested investors must submit their request to be appointed as lead plaintiff by the deadline of September 28, 2026. However, it’s important to note that engaging as a lead plaintiff isn’t a prerequisite for eligibility to share in any recovery obtained through this lawsuit.

For more details about how to proceed, investors can reach out directly to Lewis Kahn, Managing Partner at KSF, toll-free at 1-833-538-3666 or via email at [email protected]. Alternatively, more information can be found on KSF's official website.

About Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC is a premier boutique law firm focused on securities litigation and investor protections. With a reputation bolstered by significant settlements on behalf of investors, KSF has helped many recoup losses associated with corporate fraud. Founded by former Louisiana Attorney General Charles C. Foti, Jr., the firm operates from multiple locations, including New York, California, and Louisiana.

In conclusion, the situation surrounding Capricor Therapeutics, Inc. is fluid, and affected investors are strongly encouraged to act before the forthcoming deadline. It’s crucial to remain informed about developments in this case, as the implications could be far-reaching for those awaiting recovery.